Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 25,000 Shares of Company Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 25,000 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $42.91, for a total transaction of $1,072,750.00. Following the completion of the transaction, the executive vice president owned 55,755 shares in the company, valued at $2,392,447.05. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Richard Daniell also recently made the following trade(s):

• On Wednesday, November 11th, Richard Daniell sold 20,003 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $42.80, for a total transaction of $856,128.40.

Teva Pharmaceutical Industries Trading Up 0.7%

Shares of TEVA stock opened at $43.52 on Friday. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The company has a market cap of $50.72 billion, a price-to-earnings ratio of 101.22, a PEG ratio of 4.05 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.31. The firm has a fifty day moving average price of $40.00 and a 200-day moving average price of $35.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. Teva Pharmaceutical Industries’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned $0.78 EPS. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Teva Pharmaceutical Industries News Summary

Investors following TEVA have been watching these news items:

• Positive Sentiment: At its R&D Day, Teva outlined a goal of generating $6–7 billion in innovative-medicines revenue by 2030 and shared pipeline updates, including potential first-in-class treatments for Tourette syndrome, celiac disease and intestinal scarring. The growth plan and pipeline progress could strengthen the investment case, though they remain forward-looking goals. R&D Day announcement
• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
• Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. First Trust Advisors LP raised its position in shares of Teva Pharmaceutical Industries by 693.7% during the third quarter. First Trust Advisors LP now owns 84,589 shares of the company’s stock valued at $3,350,000 after buying an additional 73,932 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $1,175,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $1,648,000. USS Investment Management Ltd purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $10,840,000. Finally, WealthTrust Axiom LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $279,000. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Leerink Partners lifted their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen increased their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They set a “buy” rating and a $52.00 target price on the stock. Finally, Zacks Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.15.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.